CryoCor, Inc. to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Published: Feb 15, 2008
SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that Gregory J. Tibbitts, Chief Financial Officer, is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, CA, on Wednesday, February 20, 2008 at 1:00 p.m. PT at The Ritz Carlton Laguna Niguel.
Mr. Tibbitts will provide a general corporate update, discuss recent commercialization activity for the Company's Cardiac Cryoablation System and review recent developments in the Company's intellectual property strategy.
A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com. The recording will remain available on CryoCor's Web site for at least 30 days following presentation.
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors and the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.
CONTACT: Gregory J. Tibbitts, Chief Financial Officer, CryoCor, Inc.,
+1-858-909-2200, email@example.com; or investors, Nick Laudico,
+1-646-536-7030, firstname.lastname@example.org, or Zack Kubow, +1-646-536-7020,
email@example.com, or media, Jason Rando, +1-646-536-7025,
firstname.lastname@example.org, all of The Ruth Group for CryoCor, Inc.
Web site: http://www.cryocor.com/